Mutant protein A30P α-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics.

The Journal of Biological Chemistry
Luisel R LemkauChad M Rienstra

Abstract

α-Synuclein (AS) is associated with both sporadic and familial forms of Parkinson disease (PD). In sporadic disease, wild-type AS fibrillates and accumulates as Lewy bodies within dopaminergic neurons of the substantia nigra. The accumulation of misfolded AS is associated with the death of these neurons, which underlies many of the clinical features of PD. In addition, a rare missense mutation in AS, A30P, is associated with highly penetrant, autosomal dominant PD, although the pathogenic mechanism is unclear. A30P AS fibrillates more slowly than the wild-type (WT) protein in vitro and has been reported to preferentially adopt a soluble, protofibrillar conformation. This has led to speculation that A30P forms aggregates that are distinct in structure compared with wild-type AS. Here, we perform a detailed comparison of the chemical shifts and secondary structures of these fibrillar species, based upon our recent characterization of full-length WT fibrils. We have assigned A30P AS fibril chemical shifts de novo and used them to determine its secondary structure empirically. Our results illustrate that although A30P forms fibrils more slowly than WT in vitro, the chemical shifts and secondary structure of the resultant fibrils ar...Continue Reading

References

Nov 20, 1991·Journal of Molecular Biology·D S WishartF M Richards
Jan 1, 1994·Methods in Enzymology·D S Wishart, B D Sykes
Nov 1, 1995·Journal of Biomolecular NMR·F DelaglioA Bax
Feb 14, 1998·Journal of Biomolecular NMR·D S WishartB D Sykes
Jan 5, 2000·Journal of Magnetic Resonance·B M FungK Ermolaev
Feb 15, 2001·Archives of Neurology·J E GalvinJ Q Trojanowski
Jul 4, 2001·Nature Reviews. Neuroscience·M Goedert
Apr 25, 2002·Annual Review of Physical Chemistry·Eric Oldfield
Dec 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christopher P JaroniecRobert G Griffin
Jun 18, 2003·Journal of Magnetic Resonance·Corey R Morcombe, Kurt W Zilm
Nov 1, 2003·Science·A B SingletonK Gwinn-Hardy
Feb 3, 2004·Annals of Neurology·Juan J ZarranzJusto G de Yebenes
Apr 22, 2004·Journal of the American Chemical Society·Tatyana I IgumenovaAnn E McDermott
Sep 29, 2004·Lancet·Marie-Christine Chartier-HarlinAlain Destée
Oct 5, 2006·Journal of the American Chemical Society·Ansgar B SiemerBeat H Meier
Oct 16, 2007·Journal of Molecular Biology·Shahin ZibaeeMichel Goedert
Dec 7, 2007·The Journal of Physical Chemistry. B·Heather L Frericks SchmidtChad M Rienstra
Apr 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jonathan J HelmusChristopher P Jaroniec
Jan 7, 2009·Journal of the American Chemical Society·Benjamin J WylieChad M Rienstra
Feb 4, 2010·Journal of the American Chemical Society·Jonathan J HelmusChristopher P Jaroniec
May 4, 2010·Annals of Neurology·Kay SeidelRejko Krüger
May 22, 2010·EMBO Reports·Frédéric DariosBazbek Davletov
Jun 18, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·David A ScottSubhojit Roy
Feb 1, 2011·Protein Science : a Publication of the Protein Society·Min-Kyu ChoMarkus Zweckstetter

❮ Previous
Next ❯

Citations

Jan 22, 2014·Quarterly Reviews of Biophysics·Nicoletta PlotegherLuigi Bubacco
May 23, 2015·Journal of the American Chemical Society·Michael T ColvinRobert G Griffin
Dec 24, 2015·European Biophysics Journal : EBJ·Mark A HealeyJack A Tuszynski
Aug 31, 2016·Proceedings of the National Academy of Sciences of the United States of America·Patrick FlagmeierCéline Galvagnion
Sep 30, 2016·Expert Opinion on Investigational Drugs·Nóra TörökLászló Vécsei
Mar 1, 2016·Journal of Neurochemistry·Wouter Peelaerts, Veerle Baekelandt
Jan 12, 2017·ACS Chemical Neuroscience·Liang XuDamien Thompson
Dec 24, 2015·Organic & Biomolecular Chemistry·Conor M HaneyE James Petersson
Sep 3, 2014·Protein Science : a Publication of the Protein Society·Robert Tycko
Oct 1, 2019·Protein Engineering, Design & Selection : PEDS·Sandra RochaPernilla Wittung-Stafshede
Mar 29, 2016·Nature Structural & Molecular Biology·Marcus D TuttleChad M Rienstra
Feb 14, 2017·Methods and Applications in Fluorescence·Shruti SahaySamir K Maji
Feb 6, 2020·Proceedings of the National Academy of Sciences of the United States of America·David R BoyerDavid S Eisenberg
Nov 7, 2019·Nature Structural & Molecular Biology·David R BoyerDavid S Eisenberg
Oct 13, 2020·Frontiers in Cell and Developmental Biology·Martin KiechleKarin M Danzer
Feb 28, 2020·ACS Chemical Biology·Veronika SachsenhauserJames C A Bardwell
Apr 9, 2021·Frontiers in Cell and Developmental Biology·Michele PerniChristopher M Dobson
Mar 16, 2017·ACS Chemical Neuroscience·Arshdeep SidhuVinod Subramaniam
Jan 21, 2020·The Journal of Physical Chemistry. B·Bhisma N RathaAnirban Bhunia
Aug 10, 2017·Biochemistry·Robert SilversRobert G Griffin

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.